Meeting
2020 Genitourinary Cancers Symposium
The impact of the expression of the transcription factor MYBL2 on outcomes of patients with localized and advanced prostate cancer.
Authors
Yuki Yoshikawa
Department of Medicine,Memorial Sloan Kettering Cancer Center, New York, NY
Yuki Yoshikawa , Xin Victoria Wang , Yu-Hui Chen , Ying Zhang Mazzu , Goutam Chakraborty , Lina E. Jehane , Sai Harisha Rajanala , Rahim Hirani , Subhiksha Nandakumar , Konrad H. Stopsack , Gwo-Shu Mary Lee , Elai Davicioni , Glenn Liu , Robert S. DiPaola , Michael Anthony Carducci , Philip W. Kantoff , Christopher Sweeney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 149)
Abstract #
149
Poster Bd #
G7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Patient reported quality of life (QOL) and survival outcomes: Analysis of ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PCa).
First Author: Daniel Sentana Lledo
Poster
2023 ASCO Annual Meeting
Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial.
First Author: Ryan Phillips
Poster
2023 ASCO Genitourinary Cancers Symposium
Use of prostate cancer subtyping by gene expression to predict response to radiation and chemohormonal therapies.
First Author: Adam B Weiner
Poster
2022 ASCO Quality Care Symposium
Time trends of overall survival and other outcomes in patients with mHSPC: An observational study of U.S. EHR data (TIMES).
First Author: Neal D. Shore